menu
    • menu
    [{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Antibody, Unconjugated","year":"2024","type":"Acquisition","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apeiron Biologics","amount2":0.13,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.13,"dosageForm":"Infusion","sponsorNew":"Apeiron Biologics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Apeiron Biologics \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2024","type":"Agreement","leadProduct":"Dinutuximab","moa":"||Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II","graph3":"Essential Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Essential Pharma \/ AGC Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Essential Pharma \/ AGC Biologics"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eusa Pharma \/ BeiGene","highestDevelopmentStatusID":"15","companyTruncated":"Eusa Pharma \/ BeiGene"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Recordati","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2021","type":"Acquisition","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eusa Pharma","amount2":0.84999999999999998,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0.84999999999999998,"dosageForm":"Infusion","sponsorNew":"Eusa Pharma \/ Recordati","highestDevelopmentStatusID":"15","companyTruncated":"Eusa Pharma \/ Recordati"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Children's Oncology Group \/ National Cancer Institute"},{"orgOrder":0,"company":"New Approaches to Neuroblastoma Therapy Consortium","sponsor":"Nationwide Children\u2019s Hospital | United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2015","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase I","graph3":"New Approaches to Neuroblastoma Therapy Consortium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"New Approaches to Neuroblastoma Therapy Consortium \/ Nationwide Children\u2019s Hospital | United Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"New Approaches to Neuroblastoma Therapy Consortium \/ Nationwide Children\u2019s Hospital | United Therapeutics"},{"orgOrder":0,"company":"New Approaches to Neuroblastoma Therapy Consortium","sponsor":"United Therapeutics | National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase I","graph3":"New Approaches to Neuroblastoma Therapy Consortium","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"New Approaches to Neuroblastoma Therapy Consortium \/ United Therapeutics | National Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"New Approaches to Neuroblastoma Therapy Consortium \/ United Therapeutics | National Cancer Institute"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"Renaissance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Licensing Agreement","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"St. Jude Children \/ Renaissance Pharma","highestDevelopmentStatusID":"8","companyTruncated":"St. Jude Children \/ Renaissance Pharma"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2017","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"United Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2012","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"United Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"United Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Princess Maxima Center for Pediatric Oncology","sponsor":"Eusa Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase I","graph3":"Princess Maxima Center for Pediatric Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Princess Maxima Center for Pediatric Oncology \/ EUSA Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Princess Maxima Center for Pediatric Oncology \/ EUSA Pharma"},{"orgOrder":0,"company":"Children's Hospital Los Angeles","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase IV","graph3":"Children's Hospital Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Children's Hospital Los Angeles \/ United Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Children's Hospital Los Angeles \/ United Therapeutics"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase I","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BeOne Medicines \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"BeOne Medicines \/ Undisclosed"},{"orgOrder":0,"company":"Recordati","sponsor":"IKF Nordwest","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ITALY","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II","graph3":"Recordati","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Recordati \/ IKF Nordwest","highestDevelopmentStatusID":"8","companyTruncated":"Recordati \/ IKF Nordwest"}]

    Find Clinical Drug Pipeline Developments & Deals for Dinutuximab beta

    Menu

    Dinutuximab beta

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Apeiron Biologics

                            Austria arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Apeiron Biologics

                            Austria arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Ligand Pharmaceuticals

                            Deal Size : $128.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Ligand to Acquire APEIRON Biologics AG for $100 Million

                            Details : Ligand acquires Apeiron Biologics pipeline which also includes Qarziba (dinutuximab beta), it is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above.

                            Product Name : Qarziba

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : $100.0 million

                            July 08, 2024

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Ligand Pharmaceuticals

                            Deal Size : $128.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Princess Maxima Center for Pediatric Oncology

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Princess Maxima Center for Pediatric Oncology

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Eusa Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma

                            Details : Dinutuximab Beta is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neuroblastoma.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            July 03, 2024

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Eusa Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Essential Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Essential Pharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinutuximab,Cyclophosphamide,Topotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : AGC Biologics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Essential Pharma & AGC Biologics Partner for Immunotherapy Manufacturing for Neuroblastoma

                            Details : AGC Biologics will produce Hu1418K322A (Hu14.18), a humanised monoclonal antibody being developed for Essential Pharma for the treatment of high-risk neuroblastoma (HRNB).

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            June 11, 2024

                            Lead Product(s) : Dinutuximab,Cyclophosphamide,Topotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : AGC Biologics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            St. Jude Children

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            St. Jude Children

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Renaissance Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Renaissance Pharma Launches Today and Announces the In-Licensing of Hu14.18K322A (Hu14.18) from St. Jude Child...

                            Details : Under the agreement, Renaissance gains exclusive development, manufacturing and commercialisation rights for Hu14.18K322A, an anti GD2 humanised mAb in development by St. Jude for the treatment of newly diagnosed high-risk neuroblastoma.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            August 01, 2023

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Renaissance Pharma

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Children's Hospital Los Angeles

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Children's Hospital Los Angeles

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Sponsor : United Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rapid Administration Pilot for Infusing Dinutuximab

                            Details : Dinutuximab Beta is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Neuroblastoma.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            June 16, 2022

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Sponsor : United Therapeutics

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            BeOne Medicines

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            BeOne Medicines

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta As Maintenance Therapy in Chinese Participan...

                            Details : Dinutuximab Beta is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neuroblastoma.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            May 13, 2022

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Eusa Pharma

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Eusa Pharma

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Recordati

                            Deal Size : $847.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Recordati to Acquire Eusa Pharma (UK) Ltd, A Global Specialty Pharmaceutical Company Focused on Rare and Niche...

                            Details : Recordati will expand its pipeline by acquiring EUSA Pharma pipeline and enhances the breadth of indications which include Qarziba®, an anti-GD2 monoclonal antibody, Sylvant®, an anti-IL-6 monoclonal antibody, Fotivda®, an oral highly selective small ...

                            Product Name : Qarziba

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            December 03, 2021

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Recordati

                            Deal Size : $847.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Recordati

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Recordati

                            Italy arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : IKF Nordwest

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarco...

                            Details : Dinutuximab Beta is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leiomyosarcoma.

                            Product Name : Undisclosed

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            October 18, 2021

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : IKF Nordwest

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Eusa Pharma

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Eusa Pharma

                            France arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : BeOne Medicines

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            EUSA Pharma and BeiGene Announce Acceptance of a Biologics License Application for QARZIBA® (Dinutuximab Beta...

                            Details : QARZIBA® is a monoclonal antibody that is specifically directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells.

                            Product Name : Qarziba

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            November 09, 2020

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : BeOne Medicines

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            United Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            United Therapeutics

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            United Therapeutics Announces Study of Unituxin® (dinutuximab)

                            Details : The DISTINCT trial did not meet its primary efficacy objective of extending the overall survival with Unituxin and irinotecan versus using irinotecan alone.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            February 03, 2020

                            Lead Product(s) : Dinutuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth